Bleomycin/cisplatin/etoposide Reactions 1680, p71 - 2 Dec 2017 Neutropenia, anaemia and thrombocytopenia: 2 case reports A 16-year-old girl and a 19-year-old woman were described, who developed neutropenia and anaemia or neutropenia, anaemia and thrombocytopenia each, during treatment with bleomycin, cisplatin and etoposide [not all outcomes stated; durations of treatments to reactions onsets not stated]. Patient 1: A 16-year-old girl was diagnosed with stage IIIc small cell ovarian cancer, and was initiated on chemotherapy with the BEP regimen, which consisted of bleomycin, cisplatin and etoposide [routes and dosages not stated]. She received three cycles of chemotherapy and subsequently developed grade 4 afebrile neutropenia and grade 1 anaemia. Her disease progressed, and her regimen was changed to irinotecan and doxorubicin-liposomal. She showed disease progression, and died 6 months after the initial diagnosis of small cell ovarian cancer. Patient 2: A 19-year-old woman was diagnosed with small cell ovarian cancer, and was initiated on chemotherapy with the BEP regimen, which consisted of bleomycin, cisplatin and etoposide. She received two cycles of chemotherapy and subsequently developed grade 4 neutropenia, grade 2 anaemia and grade 4 thrombocytopenia. She was treated with unspecified granulocyte colony stimulating factors [GCSF] and erythropoietin. Her anaemia responded well to erythropoietin treatment. She later received three more cycles of etoposide and cisplatin. Her disease progressed to the liver and she was initiated on treatment with irinotecan and doxorubicin- liposomal. She died 7 months after the initial diagnosis of small cell ovarian cancer. Author comment: "[C]hemotherapy with BEP (bleomycin, etoposide, cisplatin), with relatively good tolerance, beside hematologic toxicity (afebrile gr IV neutropenia, gr I anemia)." "[R]eceived 2 cycles of BEP, with moderate tolerance (episode of gr IV neutropenia that demanded the prophylactic use of GCSF, gr II anemia that responded well to rh-EPO, gr IV thrombocytopenia)." Rovithi M, et al. Small cell ovarian cancer in adolescents: Report of two cases and review of the literature. Case Reports in Medicine 2011: Jan 2011. Available from: URL: - Greece 803283919 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial